Suppr超能文献

铜死亡模式与肺腺癌中的肿瘤突变负荷和免疫格局相关。

Cuprotosis Patterns Are Associated with Tumor Mutation Burden and Immune Landscape in Lung Adenocarcinoma.

作者信息

Liu Tingting, Cai Liangliang, Hua Hujia, Jiang Xingyu, Xu Xintian, Zhang Tianyi, Huang Wenqing, Qian Li, Bai Hua, Duan Jianchun

机构信息

College of Veterinary Medicine, Yangzhou University, Yangzhou 225001, China.

Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou 225001, China.

出版信息

J Oncol. 2022 Nov 23;2022:9772208. doi: 10.1155/2022/9772208. eCollection 2022.

Abstract

BACKGROUND

The association involving cuprotosis, molecular subtype, and specific immune cell groups in the tumor microenvironment has been focused on by more recent studies. In lung adenocarcinoma (LUAD), the potential functions of cuprotosis remain elusive.

METHODS

The cuprotosis regulations and tumor immune profile of 567 LUAD patients and the correlation between the cuprotosis patterns and the immune landscape were comprehensively evaluated. The cuprotosisScore was calculated using principal component analysis (PCA). The prognostic significance of the cuprotosisScore was evaluated by Cox regression statistics analysis.

RESULTS

Five cuprotosisClusters (named mc1, 2, 3, 4, 5)-characterized by differences in expression of immunomodulatory genes, mRNA, or lncRNA expression, and prognosis were identified. We established cuprotosisScore to quantify the cuprotosis pattern of individual LUAD patients. As is shown in further analyses, the cuprotosisScore was a relatively potential independent prognostic factor of LUAD involved in mc1. Finally, the prognostic value of the cuprotosisScore and its association with tumor immune microenvironment (iTME) of LUAD in five cuprotosisClusters were verified.

CONCLUSIONS

We demonstrated the correlation between cuprotosis modification, the molecular subtype, and tumor immune landscape in LUAD. The cuprotosisCluster with high cuprotosisScore and high tumor mutation burden (TMB) was identified with a good prognosis and immune functions. The comprehensive evaluation of cuprotosis patterns in individual LUAD patients enhances the understanding of iTME and gives a new insight toward improved immune treatment strategies for LUAD patients.

摘要

背景

最近的研究关注了铜死亡、分子亚型与肿瘤微环境中特定免疫细胞群之间的关联。在肺腺癌(LUAD)中,铜死亡的潜在功能仍不清楚。

方法

综合评估了567例LUAD患者的铜死亡调控和肿瘤免疫特征,以及铜死亡模式与免疫格局之间的相关性。使用主成分分析(PCA)计算铜死亡评分(cuprotosisScore)。通过Cox回归统计分析评估铜死亡评分的预后意义。

结果

确定了五个铜死亡簇(命名为mc1、2、3、4、5),其特征在于免疫调节基因、mRNA或lncRNA表达以及预后的差异。我们建立了铜死亡评分来量化个体LUAD患者的铜死亡模式。进一步分析表明,铜死亡评分是LUAD中涉及mc1的一个相对潜在的独立预后因素。最后,验证了铜死亡评分在五个铜死亡簇中的预后价值及其与LUAD肿瘤免疫微环境(iTME)的关联。

结论

我们证明了LUAD中铜死亡修饰、分子亚型与肿瘤免疫格局之间的相关性。确定了具有高铜死亡评分和高肿瘤突变负担(TMB)的铜死亡簇具有良好的预后和免疫功能。对个体LUAD患者铜死亡模式的综合评估增强了对iTME的理解,并为改善LUAD患者的免疫治疗策略提供了新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1623/9711958/a6f47e3535c9/JO2022-9772208.001.jpg

相似文献

1
Cuprotosis Patterns Are Associated with Tumor Mutation Burden and Immune Landscape in Lung Adenocarcinoma.
J Oncol. 2022 Nov 23;2022:9772208. doi: 10.1155/2022/9772208. eCollection 2022.
3
Molecular typing and prognostic model of lung adenocarcinoma based on cuprotosis-related lncRNAs.
J Thorac Dis. 2022 Dec;14(12):4828-4845. doi: 10.21037/jtd-22-1534.
4
6
Cross-talk of pyroptosis and tumor immune landscape in lung adenocarcinoma.
Transl Lung Cancer Res. 2021 Dec;10(12):4423-4444. doi: 10.21037/tlcr-21-715.

引用本文的文献

1
Copper homeostasis dysregulation in respiratory diseases: a review of current knowledge.
Front Physiol. 2024 May 31;15:1243629. doi: 10.3389/fphys.2024.1243629. eCollection 2024.
3
Non-apoptotic programmed cell deaths in diabetic pulmonary dysfunction: the new side of advanced glycation end products.
Front Endocrinol (Lausanne). 2023 Oct 26;14:1126661. doi: 10.3389/fendo.2023.1126661. eCollection 2023.
4
Estimating disease-free survival of thyroid cancer based on novel cuprotosis-related gene model.
Front Endocrinol (Lausanne). 2023 Sep 8;14:1209172. doi: 10.3389/fendo.2023.1209172. eCollection 2023.

本文引用的文献

1
Copper induces cell death by targeting lipoylated TCA cycle proteins.
Science. 2022 Mar 18;375(6586):1254-1261. doi: 10.1126/science.abf0529. Epub 2022 Mar 17.
2
mA modification patterns and tumor immune landscape in clear cell renal carcinoma.
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001646.
3
Visualizing and interpreting cancer genomics data via the Xena platform.
Nat Biotechnol. 2020 Jun;38(6):675-678. doi: 10.1038/s41587-020-0546-8.
5
Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
Ther Adv Med Oncol. 2019 Aug 5;11:1758835919861905. doi: 10.1177/1758835919861905. eCollection 2019.
7
Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures.
Cancer Immunol Res. 2019 May;7(5):737-750. doi: 10.1158/2326-6066.CIR-18-0436. Epub 2019 Mar 6.
8
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.
9
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Science. 2018 Oct 12;362(6411). doi: 10.1126/science.aar3593.
10
Understanding the tumor immune microenvironment (TIME) for effective therapy.
Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验